Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Del Labs merger

This article was originally published in The Tan Sheet

Executive Summary

Kelso & Company subsidiary DLI Acquisition Corp. completes purchase of Del Labs following shareholder approval, Del announces Jan. 27. Under the $480 mil. transaction, Del will become a subsidiary of DLI Holding Corp. and will no longer be publicly traded. William McMenemy will replace Dan Wassong as president and CEO. The deal was first announced last July (1"The Tan Sheet" July 5, 2004, p. 10)...

You may also be interested in...

Church & Dwight Sinks Its Teeth Into Del Labs To Acquire Orajel

Church & Dwight will augment its oral care portfolio with the addition of Del Labs' Orajel topical analgesic brand under a proposed $465 mil. acquisition announced July 2

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts